Neurocrine Biosciences Expands CRENESSITY Use to Rare CAH Subtype

Event summary

  • Neurocrine Biosciences presented first retrospective case series of CRENESSITY in 11β-hydroxylase deficiency CAH patients at ENDO 2026.
  • 15 patients showed >90% median reductions in key adrenal hormones after CRENESSITY initiation.
  • 14 of 15 patients reduced glucocorticoid doses, with 2 of 5 on antihypertensives able to reduce or discontinue them.
  • Findings represent initial clinical evidence for CRENESSITY use in this rare CAH subtype not previously studied in trials.

The big picture

This presentation marks Neurocrine's strategic push to expand CRENESSITY's clinical utility beyond its current approval for 21-hydroxylase deficiency CAH. The findings address a significant unmet need in managing 11β-hydroxylase deficiency, a rare subtype with distinct hormonal imbalances. The data could position Neurocrine as a leader in comprehensive CAH treatment, potentially opening new market opportunities. The results were presented at ENDO 2026, reinforcing the company's commitment to advancing care across the full spectrum of classic CAH.

What we're watching

Clinical Validation
Whether these preliminary results will lead to formal clinical trials for CRENESSITY in 11β-hydroxylase deficiency patients.
Market Expansion
How Neurocrine will position CRENESSITY for this rare subtype given its current approval for 21-hydroxylase deficiency.
Competitive Dynamics
The pace at which competitors may develop alternatives for this underserved CAH population.